Literature DB >> 8486169

Tumor marker CA-125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle.

A G Zeimet1, E Müller-Holzner, C Marth, G Daxenbichler, O Dapunt.   

Abstract

OBJECTIVE: To further elucidate the origin of the physiological CA-125 amounts that lead to cyclic changes in CA-125 serum levels in normally menstruating women.
DESIGN: Fifty-three normal endometria, 13 fallopian tubes, 25 ovaries, and nine isolated corpora lutea were prospectively investigated for their CA-125 content in a sandwich solid-phase RIA and by immunohistochemistry. In addition, endometrial CA-125 tissue content was compared with the actual CA-125 serum levels of the study patients.
RESULTS: Cytosolic CA-125 concentrations were 20-fold and twofold higher in the endometrium than those measured in the ovary and the fallopian tube, respectively. Moreover, only in the endometrium did CA-125 content show significant cyclic changes, with the highest concentrations during the early proliferative and middle secretory phase. The lowest tissue concentrations were measured during the early secretory phase. Furthermore, during the early and middle secretory phases cytosolic CA-125 was negatively associated with CA-125 serum levels. In immunohistochemistry, marked distributional changes in OC-125 reactivity were revealed in the basalis and the functionalis throughout the menstrual cycle and the postovulatory loss of CA-125 expression was found to be strongly connected with early secretory transformation of glandular epithelium.
CONCLUSION: Our findings indicate that the CA-125 amounts responsible for cyclic changes in serum levels in normally menstruating women seem to be a product of normal endometrium.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486169     DOI: 10.1016/s0015-0282(16)55923-8

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  9 in total

1.  The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.

Authors:  Christine C Johnson; Bruce Kessel; Thomas L Riley; Lawrence R Ragard; Craig R Williams; Jian-Lun Xu; Saundra S Buys
Journal:  Gynecol Oncol       Date:  2008-06-30       Impact factor: 5.482

2.  Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer.

Authors:  Babatunde O Akinwunmi; Ana Babic; Allison F Vitonis; Daniel W Cramer; Linda Titus; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-09-20       Impact factor: 4.254

3.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

4.  Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in Ca125 occurring during the luteal phase and the first 12 weeks of induced pregnancies.

Authors:  A M Paoletti; G G Serra; V Mais; S Ajossa; S Guerriero; M Orrù; G B Melis
Journal:  J Assist Reprod Genet       Date:  1995-04       Impact factor: 3.412

5.  A mucin-like glycoprotein identified by MAG (mouse ascites Golgi) antibodies. Menstrual cycle-dependent localization in human endometrium.

Authors:  H J Kliman; R F Feinberg; L B Schwartz; M A Feinman; E Lavi; E L Meaddough
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

6.  Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women.

Authors:  Emanuela Anastasi; Teresa Granato; Giulia Giovanna Marchei; Valentina Viggiani; Barbara Colaprisca; Sara Comploj; Maria Gabriella Reale; Luigi Frati; Cecilia Midulla
Journal:  Tumour Biol       Date:  2010-05-20

7.  How to Use CA-125 More Effectively in the Diagnosis of Deep Endometriosis.

Authors:  Marco Aurelio Pinho Oliveira; Thiers Soares Raymundo; Leila Cristina Soares; Thiago Rodrigues Dantas Pereira; Alessandra Viviane Evangelista Demôro
Journal:  Biomed Res Int       Date:  2017-06-04       Impact factor: 3.411

8.  Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort.

Authors:  Renée T Fortner; Allison F Vitonis; Helena Schock; Anika Hüsing; Theron Johnson; Raina N Fichorova; Titilayo Fashemi; Hidemi S Yamamoto; Anne Tjønneland; Louise Hansen; Kim Overvad; Marie-Christine Boutron-Ruault; Marina Kvaskoff; Gianluca Severi; Heiner Boeing; Antonia Trichopoulou; Vassiliki Benetou; Carlo La Vecchia; Domenico Palli; Sabina Sieri; Rosario Tumino; Giuseppe Matullo; Amalia Mattiello; N Charlotte Onland-Moret; Petra H Peeters; Elisabete Weiderpass; Inger Torhild Gram; Mie Jareid; J Ramón Quirós; Eric J Duell; Maria-Jose Sánchez; María Dolores Chirlaque; Eva Ardanaz; Nerea Larrañaga; Björn Nodin; Jenny Brändstedt; Annika Idahl; Kay-Tee Khaw; Naomi Allen; Marc Gunter; Mattias Johansson; Laure Dossus; Melissa A Merritt; Elio Riboli; Daniel W Cramer; Rudolf Kaaks; Kathryn L Terry
Journal:  J Ovarian Res       Date:  2017-03-20       Impact factor: 4.234

9.  Combination of noninvasive methods in diagnosis of infertile women with minimal or mild endometriosis, a retrospective study in China.

Authors:  Huaying Yu; Baijia Li; TinChiu Li; Songying Zhang; Xiaona Lin
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.